Guardian Biotechnologies is based in Saskatoon, Saskatchewan and is managed by Jim MacPherson, Chief Science Officer.  Its laboratory and offices are housed in the National Research Counsel of Canada's Plant Biotechnology Institute.

The company is developing a vaccine for the treatment of a number of serious poultry diseases including coccidiosis.  Caused by a family of parasites coccidiosis results in severe intestinal damage to young chicks followed by reduced weight gain, delay in maturity and often death.  It is estimated that coccidiosis causes the poultry industry approximately US $1.5 billion in annual losses.  A unique feature of Guardian's vaccine includes in-ovo administration, in contrast to the current industry treatment methods of spray cabinet or in-feed application of anticoccidial drugs or recombinant vaccines.

The development of a vaccine that provides broad spectrum protection against coccidiosis, cost advantages over vaccines produced from live parasites and existing drug therapies as well as dealing with drug resistance is well advanced.  A major animal health company will commence a large sample trial without cost to Guardian in Q3 of 2009.  Results are eagerly anticipated.

To find out more please join us at the Table.